Antidepressant with Novel Mechanism of Action Appears Safe and Effective in Phase 1b Clinical Trial

“Our study finds that this novel compound promotes neurogenesis in a specific part of the brain, is well tolerated and may have robust antidepressant effects. If its efficacy is confirmed in larger trials, this drug could be an important new option for patients not helped by currently available medications.” –Maurizio Fava, MD.

Dr. Fava is the executive director of the Clinical Trials Network and Institute in the Mass General Department of Psychiatry, and the director of the Division of Clinical Research at the Mass General Research Institute.

READ MORE

Leave a Reply